|
|
 |
|
Viewing report
|
|
|
|
U.S. High Throughput Screening Markets
Frost & Sullivan, Sep 2001
Combinational Chemistry Drives Demand for Sophisticated Screening Processes
Pharmaceutical and biotechnology companies are racing to identify and test
new chemical entities that may be turned into therapeutic drugs. Advances in
combinational chemistry are resulting in a large supply of chemical
compounds that need to be screened for their efficacy in fighting disease.
Consequently, demand will rise for high throughput screening (HTS)
technologies, which enable researchers to screen large numbers of
compounds quickly.
This Frost & Sullivan research investigates the potential markets for HTS
consumables (supplies and instrumentation) and services. It examines business
drivers and restraints, tracks key trends, and provides expert revenue
forecasts. With such an essential tool at its fingertips, your company will be
poised to capitalize on this important and fast-growing field.
Speed and Efficiency Define Successful HTS Solutions
Market participants are focusing research on creating assays that will speed
up the pace of HTS, says the analyst responsible for this study. Most analyses
used in HTS involve several additions and incubations at different times within
the procedure. Homogeneous assays could offer important advantages over
these processes. By mixing all the ingredients needed at once, homogeneous
assays accelerate and simplify the entire process.
Automated solutions will be in high demand. The implementation of robotics
could help ease the bottleneck of compounds waiting to be tested. Use of
ultra high throughput screening (UHTS) devices will help researchers test a
greater number of compounds per day. This study identifies areas for potential
growth, allowing your company to optimize its resources and ultimately
maximize revenues.
Innovation and Cost Reduction Should Remain Top Priorities
To remain competitive, companies performing HTS need to update their
technology and shift to more efficient and cost-saving instrumentation, says
the analyst. Coordination between robotics and HTS has not been well
established to date. But if congestion for new compounds is to be avoided,
companies must integrate new technologies quickly.
Lowering prices will also be crucial for market success. Implementing one-step
assays and automated solutions will help minimize the time to results and
reduce costs. This study reviews challenges that participants will face and
presents strategic recommendations to assist your company in developing the
most effective business plan.
Additional Information
Market Participants
Absorption Systems
Affymetrix, Inc.
Bio-Rad Laboratories
Cambrex Corp./Bioscience
Cetek Corp.
Consensus Pharmaceuticals, Inc.
Cubist Pharmaceuticals
Genelex, Corp.
Intergen, Inc.
Kosan Biosciences, Inc.
Medichem Life Sciences, Inc.
Molecular Probes, Inc.
Packard Biosciences
Reddyus Therapeutics
Xencor, Inc.
Customers who bought this item also bought
High Throughput Screening
Strategic Analysis of the European High Throughput Screening (HTS) Market
Strategic Assessment of HTS in the Asia Pacific Life Sciences Market
High Throughput Screening: Redefining the Mission, 2nd Edition
U.S. High Content Screening Markets
A Guide to HTS Assay Development
High-Throughput Screening in Drug Discovery
hERG Screening
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Toxicity Screening 2009
Opportunities in Genomics and Associated High-Throughput Screening Markets
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
|
|
|
|
